Key features and details | |
Cat. No. | MABL-1073 |
Name | Anti-CD69 mAbs |
Clone No. | AFD-2.8 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | in vivo, therapeutic, FC |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody binds human CD69. CD69 (cluster of differentiation 69), a membrane bound type II C-lectin disulfide–linked homodimer receptor, which is expressed on different leukocytes, including newly- activated lymphocytes, certain subtypes of memory T-cells, infiltrating lymphocytes isolated from patients with chronic inflammatory disorders, and regulatory T-cells. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. |
Alternative Name | AIM; BL-AC/P26; EA1; CLEC2C; GP32/28; MLR-3; Early activation antigen CD69; Activation inducer molecule; C-type lectin domain family 2 member C; Early T-cell activation antigen p60; Leukocyte surface antigen Leu-23 |
UniProt | Q07108 |
Immunogen | The original antibody was generated by fusing NS-1 myeloma cells with spleen cells from a CD69 (-/-) mouse that had previously been immunized 3 times with CD69 cells (pre-B 300-19 expressing the human CD69 molecule). |
Application Notes | This antibody can be used for the analysis of CD69 expressed on the surface of cell surface using flow cytometry (PMID: 16983725). This antibody was used as a control antibody in in vivo mouse experiments as it does not bind mouse CD69 (PMID: 16983725; 27151919). This antibody was used in a study to show control on vaccinia virus (VACV) infection in both preventive and therapeutic treatment for transgenic mice expressing human CD69. Treatment in human-CD69 transgenic mouse model with the anti-huCD69-2.8 MAb could affect the primary adaptive response to VACV infection by increasing the number of activated T cells in the periphery (PMID: 31315995). In vivo CD69 targeting in mice expressing human CD69 induced rapid and massive mobilization of bone marrow leukocytes, which was inhibited by desensitization to S1P with FTY720. |
Antibody First Published | Esplugues et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med. 2003 May 5;197(9):1093-106. PMID:12732655 |
Note on publication | Describes the generation murine antibodies against mouse CD69 and evaluates their anti-tumor activity. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
